ArticleClinical ophthalmology (Auckland, N.Z.)2023

Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study.

Piotr Kuna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.